Simponi (Golimumab) for Psoriasis

Overview
Simponi is approved by the U.S. Food and Drug Administration (FDA) to treat adults with active psoriatic arthritis. Simponi is also referred to by its drug name, golimumab. Golimumab is also sold under the brand name Simponi Aria, which has a different method of delivery.

Simponi is a biologic drug. Simponi is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Simponi is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

How do I take it?
Prescribing information states that Simponi is administered as a subcutaneous injection every four weeks after initial loading doses.

Simponi comes in a prefilled, single-dose auto-injector or syringe.

Side effects
The FDA-approved label for Simponi lists common side effects including upper respiratory tract infection and injection site reactions.

Rare but serious side effects listed for Simponi include severe fungal and viral infections, congestive heart failure, increased risk for lymphoma, demyelinating disorders such as multiple sclerosis, lupus-like syndrome, and hypersensitivity reactions.

For more details about this treatment, visit:

Simponi.com — Janssen
https://www.simponi.com/psoriatic-arthritis